Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Neupogen (filgrastim) Market Growth Performance Trended Historically, And What Lies Ahead?
Recent years have seen a robust increase in the market size of neupogen (filgrastim). Projections put its growth from $1,330.69 million in 2024 to a massive $1,404.70 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.6%. This historic growth trajectory is the result of factors such as the rise in cancer cases, heightened awareness about neutropenia induced by chemotherapy, advancements in healthcare facilities, expedited approvals for Neupogen biosimilars, and an overall increase in global healthcare expenditure.
What Is the Forecast for the Neupogen (filgrastim) Market Size Through 2029?
Anticipations suggest a robust increase in the market size of Neupogen (Filgrastim) in the coming years, expected to expand to $1,727.05 million by 2029 at a compound annual growth rate (CAGR) of 5.3%. Multiple factors contributing to this projected growth include heightening demand for affordable neutropenia treatments, blossoming healthcare infrastructure in emerging economies, escalated governmental backing for biosimilar inclusion, enhanced emphasis on individualized medicine, and an aging demographic. Upcoming market trends encompass escalated investment for R&D in biosimilars, innovations in neutropenia drug delivery methods, growing collaborations for oncology drug marketing, intensified focus on patient-centric affordability schemes, and the creation of new G-CSF products.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp
What are the Key Market Players in Neupogen (filgrastim) Market and How They’re Evolving?
Major companies operating in the neupogen (filgrastim) market include Amgen Inc.
What Are the Primary Growth Drivers in the Neupogen (filgrastim) Market?
An escalation in the frequency of diverse diseases is anticipated to be a key driver for the expansion of the neupogen (filgrastim) market. Diseases, which are essentially human body abnormalities, often result from infection, hereditary factors, environmental aspects, or lifestyle preferences, leading to unique symptoms and location-based effects. The escalating frequency of such diseases is fueled by elements like ageing demographics, inactive lifestyles, high pollution levels, poor nutrition habits and the worldwide propagation of infectious pathogens. Neupogen (filgrastim) aids in combatting the complications arising from chemotherapy-driven neutropenia through increased production of neutrophils, boosting the immune response against infections particularly in patients with weakened immunity. It plays a crucial role in reducing hospital stays, managing the risk of infection and ensuring continuous cancer care programmes for patients subjected to intensive treatments. For instance, Allergy UK, a UK-based national charity, reported in April 2024 that allergies, which became the most frequently reported chronic ailment in 2022, affected over 21 million individuals in the UK. By 2026, it is projected that at least one allergy would affect half of Europe’s population. Additionally, in June 2022, according to data published by Macmillan Cancer Support, a UK-based cancer charity, the number of cancer patients was 3 million in 2022 with predictions of nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Thus, the escalating frequency of diverse diseases drives the expansion of the neupogen (filgrastim) market. Government Healthcare Research and Development Initiatives Fuel Growth for Neupogen (filgrastim)
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp
What Are the Leading Segments in the Global Neupogen (filgrastim) Industry?
The neupogen (filgrastim)market covered in this report is segmented –
1) By Drug Type: Biologic; Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
What Are the Key Market Trends in the Neupogen (filgrastim) Industry?
A primary trend taking place in the neupogen (filgrastim) market involves a concentration on the development of innovative goods that serve as filgrastim biosimilar alternatives. These alternatives offer a cost-saving and accessible option for handling chemotherapy-induced neutropenia. Biologic medications, such as filgrastim biosimilar solutions, closely resemble their original version, Neupogen, offering similar safety, efficacy, and structure, and are used predominantly to kindle neutrophil production in chemotherapy patients to prevent neutropenia. For example, in November 2022, Releuko (filgrastim-ayow), a biosimilar of Neupogen (filgrastim), was introduced to the American market by Amneal Pharmaceuticals and Kashiv Biosciences, both US-based companies. Releuko provides both intravenous and subcutaneous options, in single-dose vials and prefilled syringes, giving healthcare providers a choice of dosing. This product holds significance for offering a cost-effective solution for chemotherapy-induced neutropenia, hence increasing the availability of critical oncology care and meeting the surge in demand for biosimilars in the market.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-
What Is the Regional Outlook for the Neupogen (filgrastim) Market?
North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19910
This Report Delivers Insight On:
1. How big is the neupogen (filgrastim) market, and how is it changing globally?
2. Who are the major companies in the neupogen (filgrastim) market, and how are they performing?
3. What are the key opportunities and risks in the neupogen (filgrastim) market right now?
4. Which products or customer segments are growing the most in the neupogen (filgrastim) market?
5. What factors are helping or slowing down the growth of the neupogen (filgrastim) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model